Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CPRX | US
0.27
1.35%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
30/08/2024
20.25
20.02
20.28
19.90
Catalyst Pharmaceuticals Inc. a commercial-stage biopharmaceutical company focuses on developing and commercializing therapies for people with rare debilitating chronic neuromuscular and neurological diseases in the United States. It offers Firdapse an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals Inc. was founded in 2002 and is based in Coral Gables Florida.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
Price Below SMA10D
Midcap (2B - 10B USD)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
25.9%1 month
56.7%3 months
40.1%6 months
39.9%35.00
9.62
3.82
0.01
0.00
15.95
4.49
-
122.45M
2.40B
2.40B
-
44.21
-
23.20
13.85
4.61
5.29
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.21
Range1M
5.53
Range3M
6.12
Rel. volume
0.62
Price X volume
14.47M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Amneal Pharmaceuticals Inc | AMRX | Drug Manufacturers-Specialty & Generic | 8.66 | 2.64B | -0.12% | n/a | -4742.26% |
Amphastar Pharmaceuticals Inc | AMPH | Drug Manufacturers-Specialty & Generic | 48.74 | 2.39B | -0.25% | 14.41 | 87.00% |
Bausch Health Companies Inc | BHC | Drug Manufacturers-Specialty & Generic | 5.93 | 2.18B | 1.02% | n/a | -1843.40% |
PAR Technology Corporation | PAR | Drug Manufacturers-Specialty & Generic | 53.99 | 1.96B | 0.11% | n/a | 65.19% |
Supernus Pharmaceuticals Inc | SUPN | Drug Manufacturers-Specialty & Generic | 35.16 | 1.94B | 0.46% | 376.00 | 4.18% |
Tilray Inc | TLRY | Drug Manufacturers-Specialty & Generic | 1.71 | 1.44B | 0.59% | n/a | 11.25% |
Harrow Health Inc | HROW | Drug Manufacturers-Specialty & Generic | 40.46 | 1.44B | 3.06% | n/a | 331.16% |
Collegium Pharmaceutical Inc | COLL | Drug Manufacturers-Specialty & Generic | 38.46 | 1.24B | -0.39% | 13.98 | 258.31% |
OPKO Health Inc | OPK | Drug Manufacturers-Specialty & Generic | 1.68 | 1.17B | 5.66% | n/a | 19.31% |
Evolus Inc | EOLS | Drug Manufacturers-Specialty & Generic | 15.89 | 1.00B | 0.38% | n/a | 656.27% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
HNI Corporation | HNI | Building Products & Equipment | 53.85 | 2.54B | 1.32% | 20.63 | 76.47% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 59.66 | 1.73B | 0.15% | 20.97 | 56.33% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.48 | 1.69B | -0.47% | 39.20 | 64.69% |
REV Group Inc | REVG | Recreational Vehicles | 31.84 | 1.65B | 1.69% | 5.64 | 63.13% |
Steelcase Inc | SCS | Building Products & Equipment | 14.14 | 1.61B | 1.87% | 17.41 | 69.98% |
Janus International Group Inc. | JBI | Building Products & Equipment | 10.99 | 1.60B | 0.92% | 11.70 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 7.07 | 1.27B | 0.43% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.74 | 1.17B | -2.65% | n/a | 19.46% |
Interface Inc | TILE | Textile Manufacturing | 18.88 | 1.10B | 0.16% | 15.75 | 106.26% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 21.94 | 990.13M | 0.14% | n/a | 3644.76% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 15.95 | - | Par |
Ent. to Revenue | 4.49 | - | Cheaper |
PE Ratio | 35.00 | 28.13 | Expensive |
Price to Book | 3.82 | 11.07 | Cheaper |
Dividend Yield | - | - | - |
Std. Deviation (3M) | 40.12 | - | Lower Risk |
Debt to Equity | 0.01 | -0.91 | Expensive |
Debt to Assets | 0.00 | 0.45 | Cheaper |
Market Cap | 2.40B | - | Emerging |